An interventional study of real-time functional magnetic resonance imaging (rt-fMRI) neurofeedback in Substance Use Disorder (SUD), sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Yale University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Substance-Related Disorders by Yale University — 6 open to participants now, 8 under way, none of them phase 3. Substance-Related Disorders · Yale University.
Among the 63 studies in Substance-Related Disorders by Yale University, this one is the 54th largest by planned enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2026, is one of 32 with no phase, and was the 63rd registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →6 of the 63 studies in Substance-Related Disorders by Yale University are open now, in 1 country. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18–50
Yale University · Sites in United States
Ages 18+ · Healthy volunteers
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 11–15 · Healthy volunteers
By country, each count listing its studies:
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 5 · Phase 4 4
First in 1993; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3 is below the median of 108 across 1,844 interventional studies indexed under Substance-Related Disorders.
Median enrollment 74 across the 59 interventional studies, 200 across the 4 observational. Of the 53 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
2 of the studies in Substance-Related Disorders by Yale University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03539575Yale UniversityCB1R in Synthetic Psychoactive Cannabinoids | 2026-12 |
| NCT07768007Yale UniversityReal-time Opioid Study | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 63 studies in Substance-Related Disorders by Yale University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This feasibility study collects initial data on the use of an fMRI neurofeedback protocol for treating anhedonia in methadone-treated individuals with opioid use disorder (OUD). The intervention tested has previously been shown to reduce anhedonia in individuals with depression and this study is collecting first-in-human data in an OUD population. Investigators will assess tolerability of the intervention and collect preliminary data from 2-3 subjects monitoring changes in anhedonia, non-substance-related autobiographical memory recall, and meaning in life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will complete five study visits. They will receive neurofeedback at two separate scanning sessions (sessions 2-3). Neurofeedback scans will include rest, neurofeedback, and transfer (i.e., no feedback) runs, one week apart.
Device: real-time functional magnetic resonance imaging (rt-fMRI) neurofeedback
A non-invasive, non-pharmacological therapeutic tool that enables an individual to learn to modulate their neural activity in order to effect behavioral change.
Number of participants who completed the intervention
Number of participants who completed the full intervention of those enrolled.
Time frame: Through study completion, up to one month post second neurofeedback session
Self-report ratings of tolerability
Questionnaire where participants indicate how worthwhile participating in the study was on a 1-7 Likert scale. Total score range 1-7 with higher numbers indicating greater tolerability.
Time frame: Up to one month post second neurofeedback session
Percentage of positive memories recalled as assessed by Autobiographical Memory Test (AMT)
A psychological assessment used to measure how specifically an individual can recall positive personal, life-related events.
Time frame: Baseline, one week post second neurofeedback session and one month post second neurofeedback session
Changes in anhedonia, as assessed by the Snaith-Hamilton Pleasure Scale (SHAPS)
Total score range 0-14 with higher scores reflecting a higher level of anhedonia (the inability to experience pleasure).
Time frame: Baseline, one week post second neurofeedback session and one month post second neurofeedback session
Plan to share: Yes — De-identified data will be shared with other researchers.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Feb 2027, 5 months after the start.
Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 5 months is below that.
Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.